Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyvanse
Pharma
Takeda looks to put generic Vyvanse woes in the rearview
The gap between Vyvanse generic sales declines and growth from new products is narrowing, Takeda said on its third-quarter 2025 earnings call.
Zoey Becker
Jan 29, 2026 1:21pm
Takeda's neuroscience field force hit with layoffs
Jan 20, 2026 2:22pm
GSK-Hengrui, Takeda, Celltrion—Fierce Pharma Asia
Aug 1, 2025 9:00am
Takeda revenue sinks on more Vyvanse-related sales woes
Jul 30, 2025 11:28am
Takeda eyes upcoming launches as Vyvanse generics hit lingers
May 8, 2025 10:36am
Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia
Sep 6, 2024 9:00am
